Lyell Immunopharma Inc (NASDAQ: LYEL) is -16.67% lower on its value in year-to-date trading and has touched a low of $0.48 and a high of $3.14 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The LYEL stock was last observed hovering at around $0.58 in the last trading session, with the day’s loss setting it -0.05%.
Currently trading at $0.53, the stock is -18.00% and -13.53% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.84 million and changing -8.34% at the moment leaves the stock -54.05% off its SMA200. LYEL registered -74.36% loss for a year compared to 6-month loss of -61.63%. The firm has a 50-day simple moving average (SMA 50) of $0.61684 and a 200-day simple moving average (SMA200) of $1.16058.
The stock witnessed a -13.82% gain in the last 1 month and extending the period to 3 months gives it a -20.45%, and is -12.04% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.18% over the week and 11.59% over the month.
Lyell Immunopharma Inc (LYEL) has around 300 employees, a market worth around $157.45M and $0.06M in sales. Profit margin for the company is -562285.25%. Distance from 52-week low is 10.87% and -83.04% from its 52-week high. The company has generated returns on investments over the last 12 months (-79.06%).
The EPS is expected to grow by 48.63% this year
141.0 institutions hold shares in Lyell Immunopharma Inc (LYEL), with institutional investors hold 76.42% of the company’s shares. The shares outstanding are 294.88M, and float is at 125.61M with Short Float at 6.44%. Institutions hold 65.93% of the Float.
The top institutional shareholder in the company is MWG MANAGEMENT LTD. with over 20.16 million shares valued at $29.24 million. The investor’s holdings represent 7.8945 of the LYEL Shares outstanding. As of 2024-06-30, the second largest holder is ORLAND PROPERTIES LTD with 15.09 million shares valued at $21.89 million to account for 5.91 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 13.5 million shares representing 5.3078 and valued at over $19.57 million, while VANGUARD GROUP INC holds 5.2697 of the shares totaling 13.4 million with a market value of $19.43 million.
Lyell Immunopharma Inc (LYEL) Insider Activity
The most recent transaction is an insider purchase by Klausner Richard, the company’s Director. SEC filings show that Klausner Richard bought 158,000 shares of the company’s common stock on Mar 14 ’25 at a price of $0.60 per share for a total of $94942.0. Following the purchase, the insider now owns 0.84 million shares.
Lyell Immunopharma Inc disclosed in a document filed with the SEC on Mar 17 ’25 that Newton Charles W. (Chief Financial Officer) bought a total of 200,000 shares of the company’s common stock. The trade occurred on Mar 17 ’25 and was made at $0.56 per share for $0.11 million. Following the transaction, the insider now directly holds 0.2 million shares of the LYEL stock.
Still, SEC filings show that on Mar 14 ’25, Seely Lynn (President and CEO) acquired 175,000 shares at an average price of $0.61 for $0.11 million. The insider now directly holds 712,500 shares of Lyell Immunopharma Inc (LYEL).
